US8765720B2ActiveUtilityA1

Combination therapy for the treatment of multiple myeloma

46
Individually held — no corporate assignee on recordPriority: May 27, 2009Filed: Nov 9, 2011Granted: Jul 1, 2014
Est. expiryMay 27, 2029(~2.8 yrs left)· nominal 20-yr term from priority
Inventors:James R. Berenson
A61K 31/4422A61P 35/00A61K 31/445
46
PatentIndex Score
0
Cited by
77
References
16
Claims

Abstract

The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
       1. A method for treating bortezomib-resistant multiple myeloma in a subject comprising administering to the subject a combination of COMPOUND 1, or a pharmaceutically acceptable ester of COMPOUND 1, or a prodrug of COMPOUND 1 and bortezomib, or a pharmaceutically acceptable ester of bortezomib, or a prodrug of bortezomib 
       
         
           
           
               
               
           
         
       
     
     
       2. The method of  claim 1 , wherein the bortezomib is administered as a prodrug. 
     
     
       3. The method of  claim 1 , wherein the bortezomib is administered at a dose in the range of about 0.5 mg/m 2  to about 2 mg/m 2 . 
     
     
       4. The method of  claim 3 , wherein the bortezomib is administered at a dose in the range of about 0.7 mg/m 2  to about 1.3 mg/m 2 . 
     
     
       5. The method of  claim 1 , wherein the bortezomib is administered pursuant to a scheduled dosing cycle in which bortezomib is administered every 3 to 7 days for 2 to 4 weeks, followed by a rest period of about 7 to 21 days during which bortezomib is not administered. 
     
     
       6. The method of  claim 5 , wherein the bortezomib is administered pursuant to a scheduled dosing cycle in which bortezomib is administered on days 1, 4, 8 and 11 of a 21 day cycle. 
     
     
       7. The method of  claim 5 , wherein the bortezomib is administered pursuant to a scheduled dosing cycle in which bortezomib is administered on days 1, 4, 8 and 11 of a 28 day cycle. 
     
     
       8. The method of  claim 1 , wherein the COMPOUND 1 is administered as a prodrug. 
     
     
       9. The method of  claim 8 , wherein the COMPOUND 1 prodrug is a pharmaceutically acceptable ester form of COMPOUND 1. 
     
     
       10. The method of  claim 1 , wherein the COMPOUND 1 is administered at a dose in the range of about 0.5 mg/m 2  to about 5 mg/m 2 . 
     
     
       11. The method of  claim 10 , wherein the COMPOUND 1 is administered at a dose in the range of about 1 mg/m 2  to about 3 mg/m 2 . 
     
     
       12. The method of  claim 11 , wherein the COMPOUND 1 is administered at a dose of about 1.5 mg/m 2 . 
     
     
       13. The method of  claim 1 , wherein the COMPOUND 1 is administered pursuant to a scheduled dosing cycle in which COMPOUND 1 is administered every 3 to 14 days for 2 to 4 weeks, followed by a rest period of about 7 to 21 days during which COMPOUND 1 is not administered. 
     
     
       14. The method of  claim 13 , wherein the COMPOUND 1 is administered pursuant to a scheduled dosing cycle in which COMPOUND 1 is administered on days 1, 4, 8 and 11 of a 21 day cycle. 
     
     
       15. The method of  claim 13 , wherein the COMPOUND 1 is administered pursuant to a scheduled dosing cycle in which COMPOUND 1 is administered on days 1, 8 and 15 of a 28 day cycle. 
     
     
       16. The method of  claim 15 , wherein the scheduled dosing cycle is repeated at least once.

Join the waitlist — get patent alerts

Track US8765720B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.